Table 1.
Patient characteristics (N=94).
| Age, yr, median (range) | 62 (18–90) |
| Male | 45 (47.9) |
| Time of diagnosis | |
| 2002–2015 | 27 (28.7) |
| 2016–2021 | 67 (71.3) |
| Palpable splenomegaly | 0 (0.0) |
| Volumetric splenomegaly | 47 (50.0) |
| Laboratory findings | |
| WBC, ×109/L | 11.0±4.2 |
| Neutrophil/lymphocyte | 3.9±2.4 |
| Monocyte, ×109/L | 0.6±0.5 |
| Hemoglobin, g/dL | 13.6±2.2 |
| Platelet, ×109/L | 948.2±387.7 |
| LDH, ×ULN | 1.2±0.4 |
| Driver gene mutation | |
| JAK2V617F | 64 (72.8) |
| CALR | 9 (9.6) |
| MPL | 3 (3.2) |
| JAK2V617F VAF, % | 24.8±12.8 |
| IPSET | |
| Low | 30 (31.9) |
| Intermediate | 27 (28.7) |
| High | 37 (39.4) |
| Comorbidity | |
| Hypertension | 32 (34.0) |
| Diabetes mellitus | 12 (13.8) |
| Chronic kidney disease | 11 (11.7) |
| Dyslipidemia | 19 (20.2) |
| Smoking | 21 (22.3) |
| Treatments | |
| Cytoreductive treatment | 65 (67.4) |
| Aspirin | 86 (91.5) |
| Initial thrombotic events | |
| Time of occurrence | |
| Before or at diagnosis | 21 (22.3) |
| After diagnosis | 1 (1.1) |
| Overall | 22 (23.4) |
| Vessels involved | |
| Arterial | 21 (22.3) |
| Venous | 1 (1.1) |
| Follow-up, yr, median (range) | 2.9 (0.12–0.2) |
Values are presented as number (%) or mean±standard deviation.
Abbreviations: CALR, calreticulin; IPSET, International Prognostic Score in Essential Thrombocythemia; LDH, lactate dehydrogenase; ULN, upper limit of normal; VAF, variant allele frequency.